Skip to main content
TipRanks
Go Ultimate75% OFF

SAMSUNG PHARMACEUTICAL.CO.,Ltd. (001360) Stock Statistics & Valuation Metrics

Total Valuation

SAMSUNG PHARMACEUTICAL.CO.,Ltd. has a market cap or net worth of KRW 124.62B. The enterprise value is KRW 134.50B.

Market Cap
KRW 124.62B
Enterprise Value
KRW 134.50B

Share Statistics

SAMSUNG PHARMACEUTICAL.CO.,Ltd. has 94,162,080 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
94,162,080
Owned by Insiders
―
Owned by Institutions
0.40%

Financial Efficiency

SAMSUNG PHARMACEUTICAL.CO.,Ltd.’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is -13.63%.

Return on Equity (ROE)
0.10
Return on Assets (ROA)
0.07
Return on Invested Capital (ROIC)
-13.63%
Return on Capital Employed (ROCE)
-0.16
Revenue Per Employee
191.98M
Profits Per Employee
48.10M
Employee Count
240
Asset Turnover
0.28
Inventory Turnover
3.07

Valuation Ratios

The current PE Ratio of SAMSUNG PHARMACEUTICAL.CO.,Ltd. is -0.85. SAMSUNG PHARMACEUTICAL.CO.,Ltd.’s PEG ratio is -0.42.

PE Ratio
-0.85
PS Ratio
2.73
PB Ratio
1.61
Price to FCF
-11.95
Price to Operating Cash Flow
-13.24
PEG Ratio
-0.42

Income Statement

In the last 12 months, SAMSUNG PHARMACEUTICAL.CO.,Ltd. had revenue of 46.07B and earned 11.55B in profits. Earnings per share was 122.66.

Revenue
46.07B
Gross Profit
14.64B
Operating Income
-19.46B
Pretax Income
11.55B
Net Income
11.55B
EBITDA
-18.06B
Earnings Per Share (EPS)
122.66

Cash Flow

In the last 12 months, operating cash flow was -8.80B and capital expenditures -13.48B, giving a free cash flow of -9.75B billion.

Operating Cash Flow
-8.80B
Free Cash Flow
-9.75B
Free Cash Flow per Share
-103.61

Dividends & Yields

SAMSUNG PHARMACEUTICAL.CO.,Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-8.37%
Earnings Yield
-117.71%

Stock Price Statistics

Beta
0.26
52-Week Price Change
-12.94%
50-Day Moving Average
1313.34
200-Day Moving Average
1541.53
Relative Strength Index (RSI)
44.61
Average Volume (3m)
323.96K

Important Dates

SAMSUNG PHARMACEUTICAL.CO.,Ltd. upcoming earnings date is Mar 24, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 16, 2026
Next Earnings Date
Mar 24, 2027
Ex-Dividend Date
―

Financial Position

SAMSUNG PHARMACEUTICAL.CO.,Ltd. as a current ratio of 0.92, with Debt / Equity ratio of 14.62%

Current Ratio
0.92
Quick Ratio
0.68
Debt to Market Cap
0.12
Net Debt to EBITDA
-0.36
Interest Coverage Ratio
-16.28

Taxes

In the past 12 months, SAMSUNG PHARMACEUTICAL.CO.,Ltd. has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

SAMSUNG PHARMACEUTICAL.CO.,Ltd. EV to EBITDA ratio is -8.17, with an EV/FCF ratio of -13.39.

EV to Sales
3.06
EV to EBITDA
-8.17
EV to Free Cash Flow
-13.39
EV to Operating Cash Flow
-14.84

Balance Sheet

SAMSUNG PHARMACEUTICAL.CO.,Ltd. has KRW 9.56B in cash and marketable securities with KRW 18.60B in debt, giving a net cash position of -KRW 9.04B billion.

Cash & Marketable Securities
KRW 9.56B
Total Debt
KRW 18.60B
Net Cash
-KRW 9.04B
Net Cash Per Share
-KRW 96.03
Tangible Book Value Per Share
KRW 598.85

Margins

Gross margin is 38.51%, with operating margin of -39.32%, and net profit margin of -320.93%.

Gross Margin
38.51%
Operating Margin
-39.32%
Pretax Margin
-320.93%
Net Profit Margin
-320.93%
EBITDA Margin
-37.40%
EBIT Margin
-39.32%

Analyst Forecast

The average price target for SAMSUNG PHARMACEUTICAL.CO.,Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
-2.43%
EPS Growth Forecast
-234.71%

Scores

Smart Score
―
AI Score
44